105 results about "Gut microbiome" patented technology

Disclosed is a strain of Bifidobacterium longum subsp. longum named dipro-O. The Bifidobacterium longum subsp. longum dipro-O used in the present invention has the ability to overproduce BSH, the ability to reduce cholesterol, and the ability to metabolize tryptophan into indole-3-lactic acid, can effectively reduce body weight, significantly lower insulin resistance levels resulting from high-fat diets, reduce the expression of the inflammatory cytokine TNF-α, significantly lower the levels of total cholesterol (TC) and low-density lipoprotein (LDL) in the blood, and increase the level of high-density lipoprotein (HDL), and can ameliorate disorders of the gut microbiome structure. In addition, the strain can also have an ameliorating effect on other lipid metabolism-related diseases such as hyperlipidemia, thereby providing health interventions for the host's body weight, liver, intestinal health, and blood lipid levels. Moreover, pasteurized dipro-O can also have the effect of regulating lipid metabolism, further extending the range of applications of the strain.

The present disclosure relates to methods of treating at least one symptom of a mental disorder or disease of the central nervous system in a subject by modulating the amount of GABA produced in the subject's gut. The present disclosure also relates to methods of culturing the bacterial strain new bacterial strains. Also disclosed are methods of identifying bacterial strains capable of producing GABA, and engineering strains to produce GABA.

Affinity-based and activity-based probes (ABPs) described herein offer transformative resolutions to microbiome function. These ABPs target key metabolic pathways in the gut microbiome. The ABPs contain a binding group, a reactive group, and a. reporter group handle that allows for the addition of a "flexible" reporter group that can be easily swapped to enable multimodal fluorescence and proteomic measurements and isolation of live cells. The binding group, also called an affinity element or biorecognition element, mirrors monomeric and polymeric carbohydrates, sulfated and acetylated carbohydrates, and peptides to afford probe selectivity.

Orally administered compositions comprising triacetin are presented that increase the concentration of short chain fatty acids in the gut, namely acetic acid, wherein the compositions comprising triacetin are palatable at desirable concentrations. The triacetin formulations can also be orally administered to a dysbiotic subject to increase short chain fatty acid (SCFA) concentrations in the gut of the subject while substantially avoiding gas production in the subject. Advantageously, administration of contemplated compositions also increases gut barrier integrity and helps restore a balanced gut microbiome.

Embodiments are directed to a UPEC conjugate peptide including a self-assembling peptide and at least one UPEC epitope. The UPEC conjugate peptide may self-assemble into a nanofiber or fibril. Compositions including the UPEC conjugate peptide may be used to treat a bacterial infection such as a urinary tract infection (UTI). The compositions and methods may be specific for pathogenic bacteria. The compositions and methods may treat the infection without altering the gut microbiome.

The present invention is directed to an oncolytic vector together with one or more antibiotics, one or more a probiotics or other microbiome-targeting compositions, and / or one or more fecal transplant for use in the treatment of cancer. The invention is also directed to a pharmaceutical composition comprising an oncolytic vector with one or more of the following: an antibiotic, a probiotic, a microbiome-targeting composition and a fecal transplant. The invention is also directed to a kit which comprises a first container, a second container, and a package insert, wherein the first container comprises at least one dose of a pharmaceutical composition containing an oncolytic vector, the second container containing one of the following: an antibiotic, a probiotic, a microbiome-targeting composition or a fecal transplant, and the package insert comprises instructions for treating a subject having cancer using the compositions of the first and second containers, wherein said probiotic, microbiome-targeting composition or fecal transplant comprises or promotes a bacterial species which improves the effect of the treatment with an oncolytic vector in a subject when said bacterial species is present in the gut microbiome of said subject, and wherein said antibiotic is effective against a bacterial species which decreases the effect of the treatment with an oncolytic vector in a subject when said bacterial species is present in the gut microbiome of said subject.

The present disclosure relates to a use of Lacticaseibacillus rhamnosus FMBL L23004 CNN in the preparation of a medicament for preventing or treating diabetes mellitus. The Lacticaseibacillus rhamnosus FMBL L23004 CNN was deposited with the China Center for Type Culture Collection (CCTCC) on 26 Jun. 2023 under the accession number CCTCC NO: M 20231099. The Lacticaseibacillus rhamnosus FMBL L23004 CNN strain has the effect of inhibiting the activity of α-glucosidase, α-amylase, and dipeptidyl peptidase IV. Administration of the strain can significantly lower oral glucose tolerance and insulin tolerance in Type 2 Diabetes Mellitus (T2DM) mice, reduce abnormal postprandial blood glucose fluctuations, decrease fasting blood glucose levels, lower fasting insulin levels, reduce blood lipid levels, and alleviate insulin resistance. The strain significantly improves the composition of the gut microbiome, increases the abundance and diversity of beneficial gut bacteria, and reduces the relative abundance of pathogenic bacteria.

Aspects of the disclosure relate to compositions and methods for modulating the immune response of a subject. The disclosure is based, in part, on compositions comprising a bacterial consortium that promotes interferon (IFN) response in the gut microbiome of a subject and enhances the anti-tumor effects of certain immune checkpoint inhibitor (ICI) therapies. In some embodiments, the compositions are useful for treating a subject having cancer.

Predicting a weight loss potential from gut microbiome data is described herein. In an example, a system accesses gut microbiome metagenomic sequence data for a subject and determines a measurement of one or more weight loss features from the gut microbiome metagenomic sequence data. The one or more weight loss features define a gut microbiome signature for weight loss response for the subject independent of a body mass index of the subject. The system determines a weight loss potential for the subject based on a comparison of the measurement of the subject to a plurality of reference measurements of the one or more weight loss features for a reference population showing variable weight loss responses. The system outputs the weight loss potential for the subject.

To provide modification of the gut microbiome to treat psychiatric disorders or diseases of the central nervous system.SOLUTION: The present disclosure relates to a method of treating at least one symptom of a psychiatric disorder or disease of the central nervous system in a subject by modulating the amount of GABA produced in the gut of the subject. The present disclosure also relates to a method of culturing novel bacterial strains. A method of identifying bacterial strains capable of producing GABA and engineering strains to produce GABA are also disclosed. The present disclosure also describes a method of identifying bacterial strains that can produce, for example, GABA under physiologically appropriate conditions, such as, physiologically appropriate pH.SELECTED DRAWING: None

The present invention provides for methods of treating biogenic amine related conditions. Further provided are methods of detecting biogenic amine related conditions, and selection of treatment for patients in need thereof.

A composition contains a combination of at least one fiber and at least one probiotic and is formulated for administration to a subject in a condition of challenged gut microbiome such that the combination of at least one fiber and at least one probiotic improves and / or maintains optimal cholesterol levels in a subject in a condition of challenged gut microbiome. Preferably the subject is experiencing a microbiome stressor, such as one or more of a dietary stressor, antibiotic, other medications, infections, intense exercise, stress, alcohol, travel and combinations thereof; more preferably at least a dietary stressor; most preferably at least a high fat diet, such as a Western high fat diet or a ketogenic diet. The method can achieve at least one result that is improving and / or maintaining optimal cholesterol levels in a subject in a condition of challenged gut microbiome.

Powder compositions comprising one or more therapeutic ingredients including fiber and processes of manufacturing the same. Such compositions can be used as a prebiotic dietary supplement to maintain and / or improve the gut microbiome and overall gut health of a human.

This document relates to methods and materials involved in assessing and / or treating a mammal having cancer (e.g., lymphoma). For example, methods and materials that can be used to determine if a mammal (e.g., a human) having cancer (e.g., lymphoma) is likely to respond to or has a cancer or a gut microbiome that makes that mammal more responsive to a particular cancer treatment are provided. Methods and materials for treating a mammal having cancer (e.g., lymphoma) are also provided.

The invention provides an application of a congee decoction in preparation of a medicine for treating cognitive impairment of diabetes mellitus. On the basis of clinical application and a large number of early-stage experimental studies which are all decocted and have curative effects, bile acid and intestinal flora metabolic disorder have key effects in the pathological process of diabetes and cognitive impairment; the invention firstly proposes that the homeostasis of bile acid and intestinal microbiota can be mediated through an'intestinal flora-bile acid-brain 'way to improve the cognitive impairment of diabetes mellitus by consistent decoction.

Compositions for influencing the gut microbiome of a mammalian subject can comprise a pharmaceutically acceptable carrier and phages at a concentration greater than or equal to 1x10 4 PFU / mL or PFU / mg, wherein the phages have tropisms that include obesity-causing bacteria and / or inflammatory bacteria associated with the gut microbiome of a mammal. Processes for preparing the disclosed compositions can include isolating the phages from environmental sources, characterizing the phages, and combining the phages with a pharmaceutically acceptable carrier in an amount greater than or equal to 1x10 4 PFU / mL or PFU / mg. Methods can include administering the disclosed compositions to a mammalian subject with or without co-administering the disclosed probiotics. Administering the disclosed compositions can reduce the concentration of obesity-causing bacteria and / or inflammatory bacteria in the gut microbiome of a mammalian subject, promote or induce weight loss, reduce inflammation, support metabolic health, and / or support a healthy balance / diversity within the gut microbiome of a mammalian subject.

The important thing about food is its effect on contracting or preventing disease. Food can aggravate or treat diseases. The unique way each person's body responds to different foods adds complexity to the problem. Identical twins cannot be recommended the same diet. Most nutrition apps offer functionalities like calorie counters, food diaries, recipes, and shopping lists. Nutritional genomics studies how genes and nutrients interact to determine an individual's outcome. Nutrition apps can influence healthy eating habits and reduce barriers to consuming healthful foods. Microbiome services analyze gut health to provide a proper health / diet plan. Gut microbiota health is linked to diseases like Alzheimer's, Parkinson's, and depression. The gut microbiome is critical to understanding nutrition and provides the foundation for personalized nutrition growth.

The present invention relates to the field of the human gut microbiome, more particularly to its effect on health and disease. Provided herein are means and methods of classifying the gut microbiome based on qPCR data. The invention also provides methods to diagnose and treat or reduce the severity of gut flora dysbiosis as well as of gastro-intestinal inflammation and inflammation-associated disorders or conditions in a subject in need thereof.

Engineered Bacteroides thetaiotaomicron (Bt) strains, including deletion mutant strains, and methods of use thereof are provided. Methods of delivering a therapeutic compound to a gut microbiome of a subject include generating an engineered Bacteroides thetaiotaomicron (Bt) strain to overproduce outer membrane vesicles (OMVs); loading a target therapeutic compound into the OMVs; and colonizing the gut microbiome of the subject with the engineered Bt strain. In some embodiments, the subject has at least one of lactose intolerance, phenylketonuria, inflammatory bowel disease, and a chronic intestinal condition.

The composition contains a combination of at least one type of fiber and at least one type of probiotic, and the combination of at least one type of fiber and at least one type of probiotic is formulated for administration to a subject with a stressed gut microbiome to improve and / or maintain optimal cholesterol levels in the subject with a stressed gut microbiome. Preferably, the subject is experiencing one or more microbiome stressors, e.g., dietary stressors, antibiotics, other drugs, infections, strenuous exercise, stress, alcohol, travel, and combinations thereof; more preferably, at least dietary stressors; most preferably, at least a high-fat diet, e.g., a Western high-fat diet or a ketogenic diet. The method can achieve at least one outcome, which is improving and / or maintaining optimal cholesterol levels in a subject with a stressed gut microbiome.

The present disclosure relates to a device for collecting gastrointestinal fluids / particles or samples. The present disclosure also relates to a process of collecting gastrointestinal fluids / particles or samples by the ingestible device. The ingestible device of the present disclosure is designed to non-invasively collect gastrointestinal particles, including biomolecules and components of the residing gut microbiome, with precise spatial resolution along the gastrointestinal (GI) tract. Upon deployment, the device's design and / or actuation mechanism facilitates the capture of gastrointestinal fluids and associated particles within those fluids. These samples are securely stored within the device until its natural egestion, after which the collected material can be subjected to further bio / chemical analyses.

Liquid compositions comprising one or more therapeutic ingredients including fiber and processes of manufacturing the same. Such compositions can be used as a prebiotic dietary supplement to maintain and / or improve the gut microbiome and overall gut health of a human.

The present invention relates to a bifidogenic prebiotic for use in promoting butyrate-producing bacteria in the gut microbiome of an infant or young child; wherein the bifidogenic prebiotic is administered to the infant prior to about 12 months of age; and the butyrate-producing bacteria are promoted in the gut microbiome of the infant or young child between about 1 and 5 years of age.

Powder compositions comprising one or more therapeutic ingredients including fiber and processes of manufacturing the same. Such compositions can be used as a prebiotic dietary supplement to maintain and / or improve the gut microbiome and overall gut health of a human.

The present disclosure relates to methods of feeding animals by providing feed additives that modulate the gut microbiome to improve the health, nutrition, and growth performance. The present disclosure further relates to methods of modulating metabolites present in the gastrointestinal tract of an animal. Such modulation includes, for example, modulating the level said metabolites.

The disclosure provides a computer-implemented method and system for detecting microbiome age of a subject. The method comprises obtaining a microbiota species profile from a fecal sample of the subject; predicting a gut microbiome and thus, gut health status as a value on a scale from diseased microbiome to healthy microbiome using a first machine learning model; in case the gut microbiome health status value is above a threshold, further predicting a microbiome age of the subject's gut microbiome using a second machine learning model; and providing a personalized report based on the gut microbiome health status value and, in case the gut microbiome health status value is above the threshold, a comparison between the microbiome age and the subject's chronological age.

Orally administered compositions comprising triacetin are presented that increase the concentration of short chain fatty acids in the gut, namely acetic acid, wherein the compositions comprising triacetin are palatable at desirable concentrations. The triacetin formulations can also be orally administered to a dysbiotic subject to increase short chain fatty acid (SCFA) concentrations in the gut of the subject while substantially avoiding gas production in the subject. Advantageously, administration of contemplated compositions also increases gut barrier integrity and helps restore a balanced gut microbiome.

The present invention relates to bacterial probiotics useful in aquaculture. Specifically, it discloses a selection of non-hemolytic, proteolytic, stress-tolerant bacterial strains with enhanced quorum- quenching capabilities. Moreover, the method allows detection of novel species of bacteria whose probiotic attributes could be massive for aquaculture. From the isolated bacteria, selected species were tested for their probiotic efficacy in Nile tilapia (Oreochromis niloticus), a key fish species in global finfish aquaculture. The species demonstrated significant efficacy in improving the health and growth performance of Nile tilapia juveniles. Specific growth rates and weight gain, and improved feed conversion ratios without adverse effects on fish health were observed. The gut microbiome was positively influenced by promoting beneficial bacteria while reducing harmful (opportunistic) species, leading to improved immune modulation. Survival rates were significantly boosted during a pathogenic challenge, and key immune genes were upregulated, indicating stronger local immune defenses. These findings show that the selected probiotic species offer substantial benefits for growth, feed efficiency, and disease resistance, emphasizing their potential for widespread application as probiotics in aquaculture.

This invention provides a comprehensive approach to anti-aging through the enhancement of Urolithin A production by targeting specific gut bacteria with a novel formulation. By combining 2-fucosyllactose, ellagic acid, HMOs, and probiotics, the formulation not only boosts Urolithin A levels but also promotes a diverse and healthy gut microbiome, leading to improved mitochondrial function and overall health.

Various embodiments of a gut microbiome modulating composition comprises a blend of a polyphenol and an oligosaccharide. Various embodiments of the polyphenol may comprise at least approximately 5% by weight chlorogenic acid. Various embodiments of the oligosaccharides may be standardized to a degree of polymerization of at least three to reduce digestibility. Administration of an effective amount of the gut microbiome modulating composition to a person or animal may stimulate the growth of at least one of Akkermansia muciniphila, Lactobacillus, and Bifidobacterium bacteria in the colon, which may reduce permeability of the colon, increases short chain fatty acid production in the colon, and / or modulate causes immunomodulation of human colon cells. The gut microbiome modulating composition may provide protective effects against obesity-related chronic diseases.